Home » Stocks » Kronos Bio

Kronos Bio, Inc. (KRON)

Stock Price: $32.28 USD -0.31 (-0.95%)
Updated Oct 21, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 1.78B
Revenue (ttm) n/a
Net Income (ttm) -25.05M
Shares Out 52.75M
EPS (ttm) -0.47
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 21, 2020
Last Price $32.28
Previous Close $32.59
Change ($) -0.31
Change (%) -0.95%
Day's Open 32.29
Day's Range 31.72 - 33.25
Day's Volume 190,726
52-Week Range 25.50 - 34.90

More Stats

Market Cap 1.78B
Enterprise Value 1.72B
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 52.75M
Float 32.64M
EPS (basic) n/a
EPS (diluted) -0.47
FCF / Share n/a
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short n/a
Short Ratio n/a
Short % of Float n/a
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio n/a
Revenue n/a
Operating Income n/a
Net Income -25.05M
Free Cash Flow n/a
Net Cash 52.81M
Net Cash / Share 0.96
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA n/a
ROE n/a
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (0)

Buy 0
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: n/a

Price Target

*No analysts have provided price targets for this stock.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Operating Income-16.82-6.65
Net Income-16.12-6.72
Shares Outstanding5.284.86
Earnings Per Share-3.05-1.38
Operating Cash Flow-15.08-6.44
Capital Expenditures-2.95-1.08
Free Cash Flow-18.03-7.52
Cash & Equivalents92.1810.23
Total Debt0.500.74
Net Cash / Debt91.699.49
Book Value-23.20-7.30
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Kronos Bio, Inc.
Country United States
Employees 45
CEO Norbert W. Bischofberger

Stock Information

Ticker Symbol KRON
Stock Exchange NASDAQ
Sector Health Technology
Industry Pharmaceuticals: Major
Unique Identifier NASDAQ: KRON
IPO Date October 9, 2020


Kronos Bio, a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel cancer therapeutics. The company's product engine focuses on dysregulated transcription factors and the transcriptional regulatory networks that drive oncogenic activity. Its lead product candidate is entospletinib, a selective inhibitor targeting spleen tyrosine kinase in acute myeloid leukemia patients. The company is also developing KB-0742, an orally bioavailable inhibitor of cyclin dependent kinase 9 for the treatment of MYC-amplified solid tumors. Kronos Bio, Inc. is founded in 2017 and is headquartered in San Mateo, California.